<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047242</url>
  </required_header>
  <id_info>
    <org_study_id>JHOC-J0173, CDR0000257566</org_study_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0173</secondary_id>
    <secondary_id>NCI-5528</secondary_id>
    <nct_id>NCT00047242</nct_id>
  </id_info>
  <brief_title>UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>The Pharmacokinetic and Safety Profile of UCN-01 in Combination With Irinotecan in Solid Tumors (Primarily Lung, Ovarian and GI Cancers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with irinotecan in&#xD;
      treating patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of UCN-01 and&#xD;
           irinotecan in patients with advanced solid tumors, primarily lung, ovarian, and&#xD;
           gastrointestinal tumors.&#xD;
&#xD;
        -  Determine the acute and chronic toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the anti-tumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive UCN-01 IV over 3 hours on day 1 and irinotecan IV over 90 minutes on days 1&#xD;
      and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of UCN-01 and irinotecan until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at&#xD;
      the recommended phase II dose.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study within 7-15&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-hydroxystaurosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy that is metastatic or unresectable and for which&#xD;
             standard curative or palliative therapy does not exist or is no longer effective&#xD;
&#xD;
               -  Gastrointestinal, lung, and ovarian malignancies are given priority&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No symptomatic cardiac dysfunction&#xD;
&#xD;
          -  No symptoms suggestive of coronary artery disease&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No symptomatic pulmonary dysfunction&#xD;
&#xD;
          -  FEV_1 greater than 75% of predicted&#xD;
&#xD;
          -  DLCO greater than 75% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Amylase no greater than 2 times ULN&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No diabetes mellitus or random glucose more than 200 mg/dL&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar biological or chemical&#xD;
             composition to UCN-01 or irinotecan (including rash and systemic allergic reaction&#xD;
             causing hypotension and respiratory distress)&#xD;
&#xD;
          -  No chronic diarrhea (more than 5 stools/day)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 14 days before, during, and for&#xD;
             at least 30 days after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior UCN-01 and irinotecan allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior mediastinal radiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 14 days since prior warfarin&#xD;
&#xD;
          -  No concurrent warfarin unless required for maintaining patency of existing, permanent&#xD;
             IV catheters&#xD;
&#xD;
          -  No concurrent commercial or other investigational anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross C. Donehower, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar;61(3):423-33. Epub 2007 Apr 12.</citation>
    <PMID>17429623</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2010</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>7-hydroxystaurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

